Tracking Brain Metabolism Without Radiation: How Deuterated Deoxyglucose Is Changing the Game
- Rachel Katz-Brull
- 3 days ago
- 3 min read
The ability to map glucose consumption in the brain has long been a cornerstone of modern medicine, particularly for spotting tumors, tracking neurodegenerative diseases, and mapping cognitive function. Historically, this has required Positron Emission Tomography (PET) scans using a radioactive tracer known as Fluorodeoxyglucose.
While incredibly effective, PET scans come with explicit downsides: ionizing radiation, high costs, and a strict limit on how frequently a patient can be scanned.
But what if we could get the exact same metabolic insights using a standard MRI machine and a completely non-radioactive sugar alternative?
A groundbreaking research poster presented by the team at the University of Torino, in collaboration with CortecNet and the Hadassah Medical Organization, showcases exactly that. Titled "Cerebral Uptake of Deuterated 2-Deoxy-D-Glucose Measured by 2H-MRS: Effects of Anesthesia," this study establishes a safer, highly stable, and radiation-free methodology for mapping brain metabolism. The study was presented at the 21st European Molecular Imaging Meeting (EMIM), which was held in Ljubljana, Slovenia, on March 24-27, 2026.
The Innovation: Deuterated 2-Deoxy-D-Glucose (DDG)
The secret lies in swapping standard hydrogen atoms with deuterium—a stable, naturally occurring, non-radioactive isotope of hydrogen. When attached to 2-Deoxy-D-glucose (forming DDG), it becomes a highly visible MRI probe.
Just like its radioactive counterpart, DDG is non-metabolizable. Cells with a high energy demand—such as active brain tissue or tumors—greedily pull DDG inside. However, once inside the cell, the metabolic machinery can't process it further, thereby trapping the DDG safely and creating a durable metabolic snapshot.
Testing the Thresholds
The research team led by Prof. Eleonora Cavallari investigated three variations of the molecule to see if changing the level of deuteration altered its efficacy:
[D2]DDG - [6,6-D2]2-deoxy-D-glucose
[D4]DDG - [3,4,6,6-D4]2-deoxy-D-glucose
[D7]DDG - [1,2,3,4,5,6,6-D7]2-deoxy-D-glucose
Key Scientific Insights From the Bench to the Scan
The study meticulously evaluated DDG both in chemical phantoms (in vitro) and in healthy animal models (in vivo) on a high-field 7T MRI scanner. The findings provide three major revelations for metabolic imaging:
1. Linear Quantification and No Water Interference
In vitro testing demonstrated that the Chemical Shift Imaging (CSI) sequence collapsed the multiple magnetic resonance signals of DDG into a single, highly distinct peak. The signal-to-contrast noise ratio (CNR) adjusted perfectly linearly with the number of deuterons and tracer concentration. Crucially, there was zero signal interference from natural water in the body, ensuring crystal-clear imaging baseline readings.
2. The Metabolic "Lock-In"
When benchmarking DDG against deuterated glucose, the difference was stark. Normal glucose metabolizes quickly, transforming into deuterated water molecules. DDG, on the other hand, caused no increase in the signal of the naturally abundant deuterium in water (HDO) over time. It accumulated swiftly in the brain, reaching a steady-state concentration of ~2 mM, and showed no detectable washout even up to 24 hours post-injection.
3. The Anesthesia Factor: Awake vs. Asleep
Because preclinical imaging often requires animal subjects to be anesthetized, the team studied the kinetic effects of isoflurane anesthesia relative to awake profiles.
Final Concentration: Identical. Anesthesia does not alter the ultimate amount of tracer accumulation in the brain at steady state.
Uptime Kinetics: Significantly different. Awake mice absorbed the DDG significantly faster, reaching peak concentrations much earlier than their anesthetized counterparts.
Moving Toward a Radiation-Free Clinical Reality
This study successfully establishes DDG as an incredibly stable, highly quantifiable probe for monitoring cerebral glucose uptake. Because it offers prolonged signal retention without degradation or toxicity, it paves the path for repeated, longitudinal metabolic monitoring.
The broader impact of this research is profound. By providing a radiation-free alternative to traditional PET scans, this methodology offers a massive preclinical foundation for future human clinical trials.
Ultimately, this could revolutionize diagnostic imaging for the most sensitive patient populations—including pregnant patients and pediatric populations—making critical brain metabolic mapping safer and more accessible than ever before.
Funding & Collaboration Note: This project was actively supported by the European Innovation Council and funded by the European Union, marking a vital step forward in translational molecular imaging. For inquiries regarding the underlying research, contact: eleonora.cavallari@unito.it.
Comments